Qilin Meng

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma.

The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma.

Journal: IUBMB life
Published: January 20, 2025

Correction: Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Correction: Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Journal: Journal of nanobiotechnology
Published: February 18, 2024

Acesulfame potassium triggers inflammatory bowel disease via the inhibition of focal adhesion pathway.

Acesulfame potassium triggers inflammatory bowel disease via the inhibition of focal adhesion pathway.

Journal: Journal of hazardous materials
Published: December 26, 2023

Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis.

Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 20, 2023

Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Journal: Journal of nanobiotechnology
Published: December 28, 2022

Turning gray selenium into a nanoaccelerator of tissue regeneration by PEG modification.

Turning gray selenium into a nanoaccelerator of tissue regeneration by PEG modification.

Journal: Bioactive materials
Published: July 07, 2021

Development and Characterization of a Novel Peptide-Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors.

Development and Characterization of a Novel Peptide-Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors.

Journal: Biomedicines
Published: June 07, 2021

Cancer-associated fibroblasts-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway.

Cancer-associated fibroblasts-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway.

Journal: International journal of biological sciences
Published: May 10, 2021
Showing 1-8 of 8

Last Updated: 09/26/2026